Table 4.
Retrospective bone marrow analysis prior to CART.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Dysplastic morphologic abnormalities prior to CART | No | No | No | No | Yes |
| Presence of Cytogenetic abnormalities before CART | Yes (1/200 45XY − 7) |
Unknown | Unknown | None | Yes (26/200 45XY − 7) |
| Presence of Molecular Changes before CART | Yes | Yes | Yes | Yes | Yes |
| Change in VAF (% before and after CART) | |||||
| TP53 | 15% to 89% | 2% to 10% | |||
| RUNX1 | 20% to 44.8% | 3.9% to 1.4% * | |||
| DNMT3A | 8% to 0.5% | ||||
| PHF6 | 41% to 86% | ||||
| CUX1 | 26% to 82% | ||||
| RAD21 | 1.5% to 10.5% | ||||
| TET2 | 3.5% to 6.5% | ||||
Abbreviations: VAF variant allelic frequency. * In patient 5, out of three mutations, only RUNX1 mutation was quantitatively compared prior and post CART.